rdf:type |
|
lifeskim:mentions |
|
pubmed:issue |
4
|
pubmed:dateCreated |
2004-8-27
|
pubmed:abstractText |
To evaluate the relative activity of the sequential administration of doxorubicin and cyclophosphamide (AC) followed by docetaxel alone, as primary systemic therapy in patients with breast cancer, using an in vivo chemosensitivity predictive assay.
|
pubmed:language |
eng
|
pubmed:journal |
|
pubmed:citationSubset |
IM
|
pubmed:chemical |
|
pubmed:status |
MEDLINE
|
pubmed:issn |
0250-7005
|
pubmed:author |
pubmed-author:AprileGiuseppeG,
pubmed-author:BazzocchiMassimoM,
pubmed-author:CedoliniCarlaC,
pubmed-author:Di LoretoCarlaC,
pubmed-author:GentileGiulianaG,
pubmed-author:LonderoVivianaV,
pubmed-author:MansuttiMauroM,
pubmed-author:MinisiniAlessandro MarcoAM,
pubmed-author:PigaAndreaA,
pubmed-author:PizzolittoStefanoS,
pubmed-author:PuglisiFabioF,
pubmed-author:SobreroAlbertoA
|
pubmed:issnType |
Print
|
pubmed:volume |
24
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
2487-93
|
pubmed:dateRevised |
2006-4-24
|
pubmed:meshHeading |
pubmed-meshheading:15330203-Adult,
pubmed-meshheading:15330203-Aged,
pubmed-meshheading:15330203-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:15330203-Breast Neoplasms,
pubmed-meshheading:15330203-Chemotherapy, Adjuvant,
pubmed-meshheading:15330203-Cyclophosphamide,
pubmed-meshheading:15330203-Doxorubicin,
pubmed-meshheading:15330203-Drug Administration Schedule,
pubmed-meshheading:15330203-Female,
pubmed-meshheading:15330203-Humans,
pubmed-meshheading:15330203-Middle Aged,
pubmed-meshheading:15330203-Neoadjuvant Therapy,
pubmed-meshheading:15330203-Taxoids
|
pubmed:articleTitle |
Tumor shrinkage evaluation during and after preoperative doxorubicin and cyclophosphamide followed by docetaxel in patients with breast cancer.
|
pubmed:affiliation |
Clinical Oncology, Breast Unit, University of Udine, Udine, Italy. fabio.puglisi@med.uniud.it
|
pubmed:publicationType |
Journal Article,
Clinical Trial
|